ERBB2 and neuroendocrine neoplasm: Studies focus on developing stable chelators (MACROPA) to prevent premature release of the radioactive isotope and evaluating the biodistribution of [225Ac]Ac-conjugates to identify suitable targeting vectors like peptides, antibodies, or small molecules for specific cancers such as neuroendocrine tumours (NETs) and HER2-positive cancers.